Terms: = Prostate cancer AND MYB, c-myb_CDS, 4602, ENSG00000118513, P10242, efg, Cmyb, c-myb AND Treatment
12 results:
1. Biphasic transcriptional and posttranscriptional regulation of myb by androgen signaling mediates its growth control in prostate cancer.
Acharya S; Anand S; Khan MA; Zubair H; Srivastava SK; Singh S; Singh AP
J Biol Chem; 2023 Jan; 299(1):102725. PubMed ID: 36410437
[TBL] [Abstract] [Full Text] [Related]
2. WHO Classification of Tumours fifth edition: evolving issues in the classification, diagnosis, and prognostication of prostate cancer.
Kench JG; Amin MB; Berney DM; Compérat EM; Cree IA; Gill AJ; Hartmann A; Menon S; Moch H; Netto GJ; Raspollini MR; Rubin MA; Tan PH; Tsuzuki T; Turjalic S; van der Kwast TH; Zhou M; Srigley JR
Histopathology; 2022 Oct; 81(4):447-458. PubMed ID: 35758185
[TBL] [Abstract] [Full Text] [Related]
3. Circ_0004087 interaction with SND1 promotes docetaxel resistance in prostate cancer by boosting the mitosis error correction mechanism.
Chen L; Song Y; Hou T; Li X; Cheng L; Li Y; Xing Y
J Exp Clin Cancer Res; 2022 Jun; 41(1):194. PubMed ID: 35659274
[TBL] [Abstract] [Full Text] [Related]
4. mybL2 disrupts the Hippo-YAP pathway and confers castration resistance and metastatic potential in prostate cancer.
Li Q; Wang M; Hu Y; Zhao E; Li J; Ren L; Wang M; Xu Y; Liang Q; Zhang D; Lai Y; Liu S; Peng X; Zhu C; Ye L
Theranostics; 2021; 11(12):5794-5812. PubMed ID: 33897882
[No Abstract] [Full Text] [Related]
5. Immune molecular profiling of a multiresistant primary prostate cancer with a neuroendocrine-like phenotype: a case report.
Williams SG; Aw Yeang HX; Mitchell C; Caramia F; Byrne DJ; Fox SB; Haupt S; Schittenhelm RB; Neeson PJ; Haupt Y; Keam SP
BMC Urol; 2020 Oct; 20(1):171. PubMed ID: 33115461
[TBL] [Abstract] [Full Text] [Related]
6. Targeting poly(ADP-ribose) polymerase and the c-myb-regulated DNA damage response pathway in castration-resistant prostate cancer.
Li L; Chang W; Yang G; Ren C; Park S; Karantanos T; Karanika S; Wang J; Yin J; Shah PK; Takahiro H; Dobashi M; Zhang W; Efstathiou E; Maity SN; Aparicio AM; Li Ning Tapia EM; Troncoso P; Broom B; Xiao L; Lee HS; Lee JS; Corn PG; Navone N; Thompson TC
Sci Signal; 2014 May; 7(326):ra47. PubMed ID: 24847116
[TBL] [Abstract] [Full Text] [Related]
7. Celastrol inhibits the growth of estrogen positive human breast cancer cells through modulation of estrogen receptor α.
Jang SY; Jang SW; Ko J
Cancer Lett; 2011 Jan; 300(1):57-65. PubMed ID: 20934245
[TBL] [Abstract] [Full Text] [Related]
8. Effects of the sesquiterpene lactone parthenolide on prostate tumor-initiating cells: An integrated molecular profiling approach.
Kawasaki BT; Hurt EM; Kalathur M; Duhagon MA; Milner JA; Kim YS; Farrar WL
Prostate; 2009 Jun; 69(8):827-37. PubMed ID: 19204913
[TBL] [Abstract] [Full Text] [Related]
9. Interplay of nuclear factor-kappaB and B-myb in the negative regulation of androgen receptor expression by tumor necrosis factor alpha.
Ko S; Shi L; Kim S; Song CS; Chatterjee B
Mol Endocrinol; 2008 Feb; 22(2):273-86. PubMed ID: 17975021
[TBL] [Abstract] [Full Text] [Related]
10. Hypomethylation of WNT5A, CRIP1 and S100P in prostate cancer.
Wang Q; Williamson M; Bott S; Brookman-Amissah N; Freeman A; Nariculam J; Hubank MJ; Ahmed A; Masters JR
Oncogene; 2007 Oct; 26(45):6560-5. PubMed ID: 17486081
[TBL] [Abstract] [Full Text] [Related]
11. Profiling molecular targets of TGF-beta1 in prostate fibroblast-to-myofibroblast transdifferentiation.
Untergasser G; Gander R; Lilg C; Lepperdinger G; Plas E; Berger P
Mech Ageing Dev; 2005 Jan; 126(1):59-69. PubMed ID: 15610763
[TBL] [Abstract] [Full Text] [Related]
12. G3139 (oblimersen) may inhibit prostate cancer cell growth in a partially bis-CpG-dependent non-antisense manner.
Lai JC; Benimetskaya L; Santella RM; Wang Q; Miller PS; Stein CA
Mol Cancer Ther; 2003 Oct; 2(10):1031-43. PubMed ID: 14578468
[TBL] [Abstract] [Full Text] [Related]
